A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial
Dinh Thiem V., Van Anh PT., Van Men C., Hung DT., Pollard AJ., Kamitani A., Tada Y., Fukuyama H., Iwasaki Y., Ariyasu M., Sonoyama T.